Physician profile
Layla C Barrera
NPI 1447788575
$932.93
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2022: $392 · 2023: $228 · 2024: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $136.14 | 2021-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $101.14 | 2021-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.02 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $84.83 | 2021-2022 | |
| Amgen INC. | $72.90 | 2022-2023 | Otezla, Repatha |
| Daiichi Sankyo INC. | $71.92 | 2022-2023 | Injectafer |
| Abbvie INC. | $69.88 | 2021-2024 | |
| Lilly USA, LLC | $68.59 | 2022-2023 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $35.02 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $32.46 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.17 | 2024 | Xarelto |
| Exact Sciences Corporation | $22.75 | 2023 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $22.27 | 2021 | |
| Shield Therapeutics INC | $21.62 | 2023 | Accrufer |
| Novo Nordisk INC | $20.67 | 2023 | Ozempic, Rybelsus |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $19.79 | 2021 | |
| Pfizer INC. | $19.05 | 2023 | |
| Esperion Therapeutics, INC. | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layla Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.